Biodesix, Inc. - a pioneer in the emerging field of personalized medicine - is providing clinically reliable methods for the early detection, diagnosis, therapeutic guidance, and monitoring in cancer and degenerative diseases. The ProTS Platform is used to rapidly discover novel diagnostics which enable the right treatment, for the right disease, at the right time.
  • THE FIRST CLINICALLY REPRODUCIBLE BLOOD TEST USING MULTIPLE PROTEIN MARKERS
  • A GROWING PIPELINE OF NEW DIAGNOSTIC PRODUCTS
  • Biodesix works with leading oncologists to rapidly analyze clinical samples using its proprietary, patented, and state-of-the-art tools to find patterns that distinguish various disease or patient states from those of the healthy population. From these patterns come clinically useful diagnostic products as well as potentially interesting biomarkers for use by researchers and pharmaceutical companies.
  • WE PROVIDE SERVICES TO LEADING CANCER CENTERS, CLINICAL RESEARCHERS AND THE PHARMACEUTICAL/BIO-TECH INDUSTRY
  • REPRODUCIBLE DIAGNOSTIC CLASSIFICATIONS AND BIOMARKER DETECTION
  • LEARN MORE
  • READ
    The June 6th
    JNCI
    publication
    VeriStratTM

    Therapeutic guidance for physicians treating non-small
    cell lung cancer.

    Learn More

    <<<Reproducible>>>

    Quick Turn Around

    Cost Effective Services